Background Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60% of …

PURPOSE Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell
lymphoma (DLBCL) fare poorly, with limited treatment options. The antibody-drug …

PURPOSE Mosunetuzumab is a bispecific antibody targeting CD20 and CD3 that redirects T
cells to engage and eliminate malignant B cells and is being developed for relapsed or …

Background Mosunetuzumab is a CD20 × CD3 T-cell-engaging bispecific monoclonal antibody
that redirects T cells to eliminate malignant B cells. In a phase 1 study, mosunetuzumab …

High-dose methotrexate-based chemotherapy is the mainstay of treatment of primary
central nervous system lymphoma (PCNSL), but relapses remain frequent. High-dose …

Background Pre-transplantation 18 F-fluorodeoxyglucose (FDG) PET-negativity is one of the
strongest predictors of outcome after high-dose therapy and autologous stem-cell transplant …

PURPOSE We conducted a phase II study evaluating pembrolizumab plus gemcitabine,
vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed …

Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma - PMC Back
to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage …

Background Copanlisib, an intravenous pan-class I PI3K inhibitor, showed efficacy and safety
as monotherapy in patients with relapsed or refractory indolent non-Hodgkin lymphoma …

Purpose We compared the efficacy of ofatumumab (O) versus rituximab (R) in combination
with cisplatin, cytarabine, and dexamethasone (DHAP) salvage treatment, followed by …